Conversely, in 2015, Boeck et al. found that although VEGF serum levels are higher in COPD patients (including those with cardiac diseases and diabetes), the values were not associated with clinically significant outcomes (FEV1s, result in 6MWT, BODE index) in COPD [33]. This evidence concerns the gene VEGFA and chronic obstructive pulmonary disease.